An interventional study of diabetes education and parent coaching support in Type 1 Diabetes, Continuous Glucose Monitoring and Behavioral Intervention, sponsored by Children's National Research Institute. Completed at 1 site in United States. Open to participants aged 10 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Children's National Research Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 468th largest by enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2022, is one of 614 with no phase, and was the 1,194th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Stanford University · Sites in United States
Ages 18–60 · Healthy volunteers
Wayne State University · Sites in United States
Ages 16–20
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 10 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 62 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 63 across the 203 observational. Of the 1,118 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
Children's National Research Institute is the lead sponsor of 127 studies on the registry; 45 are open to participants now.
Children's National Research Institute has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
115 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 115 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Consistent use of continuous glucose monitors (CGM) has the potential to improve glycemic control and related type 1 diabetes (T1D) health outcomes, however young adolescents with T1D are the least likely age group to begin and sustain use of CGM. The proposed study will conduct a feasibility trial of a behavioral intervention designed to optimize use of CGM in adolescents specifically targeting underrepresented populations in diabetes technology research.
Young adolescents (ages 10-15) with type 1 diabetes (T1D) are at high risk for deterioration of glycemic control and relatedly poor overall T1D self-management. Continuous glucose monitors (CGM) provide real-time indicators of glucose levels and alert users to hypoglycemia and hyperglycemia. Consistent, informed use of CGM has the potential to improve glycemic control and related T1D health outcomes. However, adolescents with T1D are the least likely age group to utilize CGM and significant health disparities exist in access to and use of CGM among youth from racial and ethnic minority backgrounds and youth with public insurance. Adolescent CGM users also continue to evidence A1c levels above recommended targets, potentially due challenges related to perceived CGM burden and related family functioning. Novel, developmentally targeted interventions delivered early in adolescence could promote optimal uptake and use of CGM and reduce psychosocial barriers to sustained use but must be evaluated in rigorous pilot trials that attend to health disparities. The current study proposes to evaluate an innovative behavioral intervention that utilizes certified diabetes care and education specialists (CDCES) to teach problem-solving and communication skills around CGM data and use, targeting adolescent-parent T1D interactions related to glucose data, individualized CGM challenges, and weekly adolescent-parent joint review of CGM reports. The intervention also addresses HCP knowledge of health disparities in diabetes technology through interactive education, and boosts family support through connection with peer parent consultants. This study aims to evaluate the preliminary efficacy of the behavioral intervention to enhance CGM use and resulting T1D health outcomes. Sixty adolescents and their parents (using a dyad study design) will be recruited for this pilot randomized trial, randomly assigned to either an immediate intervention group or a delayed intervention group serving as a standard care comparison. Intervention content will be delivered via 3 telemedicine sessions with adolescents and a parent and supported by connection with a peer parent consultant. Medical and psychosocial data (including A1c, CGM indicators, CGM burdens and benefits, diabetes distress, and diabetes-related family conflict) will be collected from adolescents and a parent at baseline and three follow-up time points across the first year after CGM initiation. The investigators will employ quantitative and qualitative analyses to evaluate intervention feasibility, acceptability, and impact. Enhancing CGM access and use at this key developmental juncture provides an excellent opportunity for tailored support and problem-solving, resulting in potentially lasting improvement in diabetes self-management. Results of this pilot trial will directly inform a multi-site randomized clinical trial to evaluate efficacy, with the long term goal of identifying effective behavioral strategies that can be integrated into routine diabetes education and care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to the immediate intervention group will participate in 3 video-conferencing sessions with a Certified Diabetes Care and Education Specialist (CDCES) interventionist and connect with a peer parent consultant immediately post randomization (expected intervention duration: 3 months).
Behavioral: diabetes education and parent coaching support
Participants randomized to the delayed intervention group will receive no intervention for 6 months post-randomization; after the 6-month follow-up period, the delayed intervention group also will participate in 3 video conferencing sessions with a CDCES interventionist and connect with a peer parent consultant (expected intervention duration: 3 months).
Behavioral: diabetes education and parent coaching support
Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
Glycemic Control
Hemoglobin A1c (HbA1c)
Time frame: 6 months post-randomization
Glycemic Control
Hemoglobin A1c (HbA1c)
Time frame: 12 months post-randomization
CGM Time-in-range
CGM time-in-range is the amount of time a person with diabetes spends in a target glucose range of 70 and 180 mg/dL. The time frame used was 90-day CGM data, with the end date of the 90 days being the 6-month timepoint start date.
Time frame: 6 months post-randomization
CGM Time-in-range
CGM time-in-range is the amount of time a person with diabetes spends in a target glucose range of 70 and 180 mg/dL. The time frame used was 90-day CGM data, with the end date of the 90 days being the 12-month timepoint start date.
Time frame: 12 months post-randomization
CGM Wear-time
The duration of time that the CGM is worn on the body. The time frame used was 90-day CGM data, with the end date of the 90 days being the 6-month timepoint start date.
Time frame: 6 months post randomization
CGM Wear-time
The duration of time that the CGM is worn on the body. The time frame used was 90-day CGM data, with the end date of the 90 days being the 12-month timepoint start date.
Time frame: 12 months post-randomization
Caregiver-Reported Family Conflict
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 6-month caregiver-reported diabetes family conflict is reported here.
Time frame: 6 months post-randomization
Caregiver-Reported Family Conflict
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 12-month caregiver-reported diabetes family conflict is reported here.
Time frame: 12 months post-randomization
Youth-Reported Family Conflict
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 6-month youth-reported diabetes family conflict is reported here.
Time frame: 6 months post-randomization
Youth-Reported Family Conflict
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 12-month youth-reported diabetes family conflict is reported here.
Time frame: 12 months post-randomization
Caregiver CGM Benefits and Burdens
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 6-month caregiver-reported Ben/Bur CGM is reported here.
Time frame: 6 months post randomization
Caregiver CGM Benefits and Burdens
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 12-month caregiver-reported Ben/Bur CGM is reported here.
Time frame: 12 months post randomization
Youth CGM Benefits and Burdens
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 6-month youth-reported Ben/Bur CGM is reported here.
Time frame: 6 months post randomization
Youth CGM Benefits and Burdens
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 12-month youth-reported Ben/Bur CGM is reported here.
Time frame: 12 months post randomization
Child/Teen Diabetes Distress
Problem Areas in Diabetes Children (PAID-C) and Teen (PAID-T) versions measure diabetes-specific emotional distress for children and adolescents. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Items are summed to create an overall distress score, with higher scores indicating greater emotional distress. For the PAID-T and PAID-C, higher scores reflect greater diabetes-specific diabetes distress for both teens and children. Scores range from 14-84 for the PAID-T and 11-66 for the PAID-C. To address the unequal sample sizes between the PAID-C (n=19) and PAID-T (n=41), scores were normalized by converting the raw scores into percentages of the maximum possible score for each version. This normalization ensured that both the child and teen versions of the PAID were on the same scale (0-100%), allowing for more accurate comparisons across groups and improving statistical power. Data here is for youth at 6-months.
Time frame: 6 months post-randomization
Child/Teen Diabetes Distress
Problem Areas in Diabetes Children (PAID-C) and Teen (PAID-T) versions measure diabetes-specific emotional distress for children and adolescents. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Items are summed to create an overall distress score, with higher scores indicating greater emotional distress. For the PAID-T and PAID-C, higher scores reflect greater diabetes-specific diabetes distress for both teens and children. Scores range from 14-84 for the PAID-T and 11-66 for the PAID-C. To address the unequal sample sizes between the PAID-C (n=19) and PAID-T (n=41), scores were normalized by converting the raw scores into percentages of the maximum possible score for each version. This normalization ensured that both the child and teen versions of the PAID were on the same scale (0-100%), allowing for more accurate comparisons across groups and improving statistical power. 12-month youth date is presented here.
Time frame: 12 months post-randomization
Caregiver Diabetes Distress
The Problem Areas in Diabetes Survey - Parent Revised version (PAID-PR) assesses the perceived parental burden associated with caring for a child with diabetes. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Each of the 18 items is reverse scored (0 to 4, 1 to 3, etc.), then you calculate the mean of all non-missing items. That mean is multiplied by 25 to produce a total score ranging from 0 to 100, with higher scores indicating greater parent diabetes-related distress. 6-month caregiver-reported diabetes distress is reported here.
Time frame: 6 months post-randomization
Caregiver Diabetes Distress
The Problem Areas in Diabetes Survey - Parent Revised version (PAID-PR) assesses the perceived parental burden associated with caring for a child with diabetes. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Each of the 18 items is reverse scored (0 to 4, 1 to 3, etc.), then you calculate the mean of all non-missing items. That mean is multiplied by 25 to produce a total score ranging from 0 to 100, with higher scores indicating greater parent diabetes-related distress. 12-month caregiver-reported diabetes distress is reported here.
Time frame: 12 months post-randomization
Caregiver-Reported Diabetes Self-Management
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 6-month caregiver-reported Diabetes Self-Management is reported here.
Time frame: 6 months post-randomization
Caregiver-Reported Diabetes Self-Management
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 12-month caregiver-reported Diabetes Self-Management is reported here.
Time frame: 12 months post-randomization
Youth-Reported Diabetes Self-Management
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 6-month youth-reported Diabetes Self-Management is reported here.
Time frame: 6 months post-randomization
Youth-Reported Diabetes Self-Management
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 12-month youth-reported Diabetes Self-Management is reported here.
Time frame: 12 months post-randomization
From Sept 2022 to January 2024, research assistants pre-screened potentially eligible dyads using the EHR. Once identified, families were mailed recruitment letters and followed up by email, phone, text, and/or in-clinic to verify eligibility and family interest. If the youth and caregiver met eligibility criteria, the team explained the study in detail and offers ample opportunities to ask questions. Once interest is confirmed, an orientation visit is scheduled to enroll and randomize dyads
| Milestone | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Started | 31 | 29 |
| Completed | 29 | 29 |
| Not completed | 2 | 0 |
Hemoglobin A1c (HbA1c)
| % of HbA1c | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Glycemic Control | 10.054 ± 2.000 | 10.338 ± 2.002 |
Hemoglobin A1c (HbA1c)
| % of HbA1c | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Glycemic Control | 9.857 ± 1.943 | 9.838 ± 1.710 |
CGM time-in-range is the amount of time a person with diabetes spends in a target glucose range of 70 and 180 mg/dL. The time frame used was 90-day CGM data, with the end date of the 90 days being the 6-month timepoint start date.
| % of time in range | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| CGM Time-in-range | 31.458 ± 14.913 | 31.750 ± 15.905 |
CGM time-in-range is the amount of time a person with diabetes spends in a target glucose range of 70 and 180 mg/dL. The time frame used was 90-day CGM data, with the end date of the 90 days being the 12-month timepoint start date.
| % of time in range | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| CGM Time-in-range | 31.350 ± 14.242 | 38.100 ± 15.483 |
The duration of time that the CGM is worn on the body. The time frame used was 90-day CGM data, with the end date of the 90 days being the 6-month timepoint start date.
| % of wear time | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| CGM Wear-time | 59.266 ± 30.258 | 45.795 ± 26.829 |
The duration of time that the CGM is worn on the body. The time frame used was 90-day CGM data, with the end date of the 90 days being the 12-month timepoint start date.
| % of wear time | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| CGM Wear-time | 54.482 ± 26.244 | 48.331 ± 28.746 |
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 6-month caregiver-reported diabetes family conflict is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver-Reported Family Conflict | 27.407 ± 8.102 | 28.040 ± 8.507 |
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 12-month caregiver-reported diabetes family conflict is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver-Reported Family Conflict | 26.357 ± 6.951 | 26.591 ± 7.854 |
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 6-month youth-reported diabetes family conflict is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Youth-Reported Family Conflict | 28.308 ± 9.190 | 27.480 ± 8.549 |
The Diabetes Family Conflict Scale-Revised (DFCS-R) was used to measure diabetes-related family conflict. Total scores are reported below. The DFCS-R is on a scale of 19-57, where a higher score indicates higher family conflict. 12-month youth-reported diabetes family conflict is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Youth-Reported Family Conflict | 28.538 ± 9.672 | 23.952 ± 5.945 |
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 6-month caregiver-reported Ben/Bur CGM is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver Benefits of CGM Use | 4.380 ± 1.082 | 4.660 ± 0.467 |
| Caregiver Burdens of CGM Use | 1.856 ± 0.407 | 1.868 ± 0.561 |
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 12-month caregiver-reported Ben/Bur CGM is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver Benefits of CGM Use | 4.513 ± 0.838 | 4.696 ± 0.479 |
| Caregiver Burdens of CGM Use | 2.036 ± 0.730 | 1.886 ± 0.925 |
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 6-month youth-reported Ben/Bur CGM is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Youth Benefits of CGM Use | 4.282 ± 0.388 | 4.390 ± 0.478 |
| Youth Burdens of CGM Use | 2.153 ± 0.522 | 2.050 ± 0.621 |
The Benefits and Burdens of CGM (Ben/Bur CGM) questionnaire includes two 8-item scales (benefits, burdens) that provide important patient-reported outcome metrics to further understand complex behaviors related to adherence to CGM use and diabetes self-management. Each questionnaire (benefits, burdens) contains eight items which are rated on a Likert scale, one to five. 1 is strongly disagree and 5 is strongly agree. Mean total scores for each scale as well as mean scores for each item may be analyzed. Scores range from 1-5 for each item/subscale and for the overall score. Higher mean score on the benefits scale indicates higher perceived benefits while higher mean scores on the burdens scales indicated higher perceived burdens. 12-month youth-reported Ben/Bur CGM is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Youth Benefits of CGM Use | 4.317 ± 0.500 | 4.631 ± 0.404 |
| Youth Burdens of CGM Use | 2.163 ± 0.762 | 2.000 ± 0.647 |
Problem Areas in Diabetes Children (PAID-C) and Teen (PAID-T) versions measure diabetes-specific emotional distress for children and adolescents. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Items are summed to create an overall distress score, with higher scores indicating greater emotional distress. For the PAID-T and PAID-C, higher scores reflect greater diabetes-specific diabetes distress for both teens and children. Scores range from 14-84 for the PAID-T and 11-66 for the PAID-C. To address the unequal sample sizes between the PAID-C (n=19) and PAID-T (n=41), scores were normalized by converting the raw scores into percentages of the maximum possible score for each version. This normalization ensured that both the child and teen versions of the PAID were on the same scale (0-100%), allowing for more accurate comparisons across groups and improving statistical power. Data here is for youth at 6-months.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Child/Teen Diabetes Distress | 48.160 ± 19.616 | 42.658 ± 20.632 |
Problem Areas in Diabetes Children (PAID-C) and Teen (PAID-T) versions measure diabetes-specific emotional distress for children and adolescents. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Items are summed to create an overall distress score, with higher scores indicating greater emotional distress. For the PAID-T and PAID-C, higher scores reflect greater diabetes-specific diabetes distress for both teens and children. Scores range from 14-84 for the PAID-T and 11-66 for the PAID-C. To address the unequal sample sizes between the PAID-C (n=19) and PAID-T (n=41), scores were normalized by converting the raw scores into percentages of the maximum possible score for each version. This normalization ensured that both the child and teen versions of the PAID were on the same scale (0-100%), allowing for more accurate comparisons across groups and improving statistical power. 12-month youth date is presented here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Child/Teen Diabetes Distress | 45.504 ± 21.615 | 40.590 ± 20.895 |
The Problem Areas in Diabetes Survey - Parent Revised version (PAID-PR) assesses the perceived parental burden associated with caring for a child with diabetes. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Each of the 18 items is reverse scored (0 to 4, 1 to 3, etc.), then you calculate the mean of all non-missing items. That mean is multiplied by 25 to produce a total score ranging from 0 to 100, with higher scores indicating greater parent diabetes-related distress. 6-month caregiver-reported diabetes distress is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver Diabetes Distress | 40.093 ± 22.988 | 42.035 ± 22.635 |
The Problem Areas in Diabetes Survey - Parent Revised version (PAID-PR) assesses the perceived parental burden associated with caring for a child with diabetes. Responses target how much each diabetes-related experience bothers/upsets the individual respondent over the past month. Each of the 18 items is reverse scored (0 to 4, 1 to 3, etc.), then you calculate the mean of all non-missing items. That mean is multiplied by 25 to produce a total score ranging from 0 to 100, with higher scores indicating greater parent diabetes-related distress. 12-month caregiver-reported diabetes distress is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver Diabetes Distress | 41.404 ± 20.518 | 39.962 ± 24.472 |
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 6-month caregiver-reported Diabetes Self-Management is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver-Reported Diabetes Self-Management | 75.638 ± 11.504 | 78.395 ± 14.409 |
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 12-month caregiver-reported Diabetes Self-Management is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Caregiver-Reported Diabetes Self-Management | 76.581 ± 10.464 | 78.287 ± 14.308 |
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 6-month youth-reported Diabetes Self-Management is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Youth-Reported Diabetes Self-Management | 72.630 ± 11.531 | 74.810 ± 14.880 |
The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management. 12-month youth-reported Diabetes Self-Management is reported here.
| Scores on a scale | Immediate Intervention | Wait-list/Delayed Intervention |
|---|---|---|
| Youth-Reported Diabetes Self-Management | 77.258 ± 12.501 | 80.968 ± 12.686 |
Collected over From the date of enrollment until the end of the follow-up period at 12 months post-randomization.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Intervention - Youth | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Wait-list/Delayed Intervention: Intervention - Youth | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| Immediate Intervention - Caregivers | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Wait-list/Delayed Intervention: Intervention - Caregivers | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
The immediate intervention had 31 dyads (31 youth, 31 caregivers) totaling 62 participants. The delayed intervention had 29 dyads (29 youth, 29 caregivers) totaling 58 participants. This is a total of 60 dyads (120 individual participants).
| Age, Categorical(Participants) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| Youth Age — <=18 years | 31 | 29 | 60 |
| Youth Age — Between 18 and 65 years | 0 | 0 | 0 |
| Youth Age — >=65 years | 0 | 0 | 0 |
| Caregiver Age — <=18 years | 0 | 0 | 0 |
| Caregiver Age — Between 18 and 65 years | 31 | 29 | 60 |
| Caregiver Age — >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| Youth Sex — Female | 11 | 14 | 25 |
| Youth Sex — Male | 20 | 15 | 35 |
| Caregiver Sex — Female | 25 | 26 | 51 |
| Caregiver Sex — Male | 6 | 3 | 9 |
| Race/Ethnicity, Customized(Participants) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| Youth Race/Ethnicity — Black, non-Hispanic | 17 | 15 | 32 |
| Youth Race/Ethnicity — Hispanic/Latine | 8 | 8 | 16 |
| Youth Race/Ethnicity — White, non-Hispanic | 3 | 2 | 5 |
| Youth Race/Ethnicity — Another racially minoritized identity | 3 | 4 | 7 |
| Caregiver Race/Ethnicity — Black, non-Hispanic | 16 | 13 | 29 |
| Caregiver Race/Ethnicity — Hispanic/Latine | 7 | 8 | 15 |
| Caregiver Race/Ethnicity — White, non-Hispanic | 4 | 5 | 9 |
| Caregiver Race/Ethnicity — Another racially minoritized identity | 4 | 3 | 7 |
| Benefits and Burdens of CGM Use(Points) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| Benefits of CGM Use - Caregiver | 4.484 ± 0.728 | 4.224 ± 1.169 | 4.358 ± 0.967 |
| Burdens of CGM Use - Caregiver | 1.995 ± 0.734 | 1.825 ± 0.542 | 1.913 ± 0.649 |
| Benefits of CGM Use - Youth | 4.236 ± 0.597 | 4.338 ± 0.617 | 4.285 ± 0.604 |
| Burdens of CGM Use - Youth | 1.968 ± 0.696 | 1.990 ± 0.526 | 1.979 ± 0.615 |
| Problem Areas in Diabetes Scale (PAID)(Points) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| PAID-T (teen) | 36.905 ± 15.046 | 34.053 ± 15.389 | 35.561 ± 14.893 |
| PAID-C (child) | 27.670 ± 15.220 | 34.867 ± 13.251 | 31.079 ± 14.404 |
| PAID-PR (parent) | 55.968 ± 20.625 | 45.284 ± 19.202 | 50.975 ± 20.343 |
| Diabetes Family Conflict Scale(Points) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| DFCS Caregiver | 32.581 ± 10.145 | 28.000 ± 6.176 | 30.300 ± 8.701 |
| DFCS Youth | 28.467 ± 8.553 | 29.107 ± 8.800 | 28.746 ± 8.531 |
| Diabetes Management Questionnaire(Points) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| DMQ Caregiver | 75.521 ± 10.839 | 78.967 ± 11.506 | 77.187 ± 11.206 |
| DMQ Youth | 76.628 ± 9.116 | 76.602 ± 13.119 | 76.615 ± 11.133 |
| HbA1c(% of HbA1c) | Immediate Intervention | Wait-list/Delayed Intervention | Total |
|---|---|---|---|
| Mean | 10.7 ± 2.2 | 10.5 ± 1.9 | 10.6 ± 2.0 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Jan 2025, 27 months.
Results were first posted in Oct 2026, 1 year 9 months after primary completion.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 27 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Jan 2022 → Sep 2022 and completion Dec 2026 → Jan 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's National Research Institute →